Estrogen and its receptor alpha (ERa) have been implicated in the tissue-specific tumorigenesis associated with BRCA1 mutations. However, the majority of breast cancers developed in human BRCA1 mutation carriers are ERa-negative, challenging the link between BRCA1 and estrogen/ERa in breast cancer formation. Using a mouse model lacking the full-length form of BRCA1, here we show that ERa is highly expressed in the premalignant mammary gland and initiation stages of tumorigenesis, although its expression is gradually diminished during mammary tumor progression. We demonstrate that the absence of full-length BRCA1 increases sensitivity of cells to estrogen-induced extracellular signal-regulated kinase 1/2 phosphorylation and cyclin D1 expression. The absence of BRCA1 turns the proliferation of ERa-positive cells from a paracrine fashion to an autocrine or endocrine fashion. Consequently, BRCA1-mutant cells are sensitized to estrogen-induced cell proliferation in vitro and mammary tumorigenesis in vivo. These findings illustrate a molecular mechanism for estrogen/ERa signals in BRCA1-associated tissue-specific tumor formation, and identify several key elements in the estrogen/ERasignaling cascade that can serve as potential therapeutic targets for BRCA1-associated tumorigenesis.
Introduction
Breast cancer is a leading cause of cancer mortality among women in the Western world. Germline mutations of BRCA1 cause about half of familial breast cancer and most familial breast and ovarian cancers (Alberg et al., 1999) . Mounting evidence indicates that BRCA1 plays essential functions in many biological processes, including transcription regulation, cell cycle regulation, chromatin remodeling, DNA damage repair and centrosome duplication (Venkitaraman, 2002; Deng, 2006) . As many of these functions of BRCA1 are not tissue specific, this raises a question of why BRCA1-associated tumorigenesis is largely confined to the breast and ovary.
Theories have been developed about this tissuespecific tumorigenesis (Elledge and Amon, 2002; Monteiro, 2003; Trauernicht and Boyer, 2003) . Because BRCA1 is expressed at higher levels in the breast and ovary than in most other tissues/organs (Miki et al., 1994; Lane et al., 1995) , it is conceivable that BRCA1 does not have an indispensable role in other tissues, where it is expressed at low levels. DNA damage triggered by BRCA1 deficiency in these tissues can be repaired efficiently by other proteins performing the similar function as BRCA1, whereas in mammary and ovarian tissues, these other proteins may not be expressed at adequate levels to conduct efficient repairing. Another theory hypothesized that the loss of heterozygosity (LOH) at the BRCA1 locus in BRCA1 mutation carriers is a rate-limiting step for tumorigenesis, and the LOH of BRCA1 could occur at higher rates in breast and ovary than in other tissue (Monteiro, 2003) . It has also been proposed that BRCA1 mutations are better tolerated in breast tissue because of the presence of some, yet unidentified, environment surviving factors. The accumulation of further mutations eventually results in tumor formation, while in other tissues the mutation of BRCA1 results in cell death (Elledge and Amon, 2002) . This hypothesis is consistent with observations that tissue-specific disruption of mouse BRCA1 results in mammary tumor formation at low frequency after a long latency (Xu et al., 1999) , suggesting additional factors are required for tumor formation. All the tumors analysed exhibited extensive genetic alterations, including overexpression and/or amplification of oncogenes and loss of function of tumor suppressors, such as p53 (Xu et al., 1999 .
It has also been proposed that estrogen signaling may serve as a good candidate that contributes to BRCA1-associated tissue-specific cancer formation (Trauernicht and Boyer, 2003) . A number of investigations performed in cultured cells revealed that BRCA1 specifically inhibits estrogen/ERa transcription activation in either estrogen-dependent (Fan et al., 1999) or estrogenindependent ways (Zheng et al., 2001) . It was reported recently that BRCA1 inhibits estrogen biosynthesis through modulating aromatase expression in ovarian granulosa cells (Hu et al., 2005) . Data obtained from numerous in vivo observations indicated that estrogen could promote breast cancer formation and, conversely, the administration of tamoxifen, which blocks ERa signaling reduced cancer risk (Prall et al., 1998; Calderon-Margalit and Paltiel, 2004; Gadducci et al., 2005) . Moreover, oophorectomy in human BRCA1 mutation carriers and in mouse mutants carrying mammary-specific BRCA1 mutations also significantly reduced the frequency of breast/mammary cancer formation (Kauff et al., 2002; Bachelier et al., 2005) . However, the majority of breast cancers developed in human BRCA1 mutation carriers were ERa-negative (Johannsson et al., 1997; Karp et al., 1997; Eisinger et al., 1999) . Owing to the lack of knowledge on how ERa-negative cancer arises, this clinical observation is inconsistent with the model, through which estrogen/ ERa is involved in BRCA1-associated tissue-specific tumorigenesis.
In this study, we have examined expression of ERa and its downstream genes in mutant mice missing BRCA1 full-length protein (Brca1
), which died during gestation but could survive to adulthood when one wild-type allele of p53 was also mutated . Our analysis revealed an important role of estrogen/ERa signaling in BRCA1-associated tissue-specific tumor formation.
Results

Increased mammary branching morphogenesis in
þ /À mice We have previously shown that deletion of full-length BRCA1 in mammary tissues caused increased apoptosis and impaired branching morphogenesis, and that haploid loss of p53 accelerated mammary tumor formation (Xu et al., 1999) . To study the cellular and molecular changes associated with mammary tumorigenesis, we examined mammary gland development in Brca1
þ /À mice. Our analysis did not reveal obvious abnormalities during mammary cycles of mice younger than 3 months (Figure 1a and 
þ /À than in control mice (Figure 1c-f ). Because these phenotypes are found in all 11 mutant animals in comparison with 11 littermate control mice in the same genetic background, we conclude that haploid loss of p53 in BRCA1-mutant mice resulted in enhanced branch morphogenesis.
The absence of full-length BRCA1 results in activation of estrogen/ERa signaling in the mammary epithelium and in early stages of tumorigenesis Because the majority of BRCA1-associated human breast cancers are negative for ERa, we examined expression of ERa in the mammary glands of virgin mice (n ¼ 14). To our surprise, we found that about 2.4-fold more mammary epithelial cells in Brca1
mice expressed ERa than those in control mice (64.873.89 vs 27.270.9%, Po0.001, Figure 1g and h). A significant higher percentage of 5-bromodeoxyuridine (BrdU)-positive cells was also detected in the epithelium of mutant glands than control glands (26.373.51 vs 6.570.99%, Po0.0001) (Figure 1i and j) . This observation indicates that absence of full-length BRCA1 increased ERa-positive cells that are correlated with increased cell proliferation. þ /À mutant (a, c) and p53 þ /À (b, d) mice, which were analysed at diestrus (I/II) stage. The ages of mice were 2 months (a, b) and 7 months (c, d), respectively. Arrows point to lymph nodes. Boxed areas are enlarged in (e, f), which show more extensive branching (arrowhead). Arrowhead points to a hyperplastic focus (that is, abnormal growth in a part of mammary gland, caused by an excessive multiplication of cells). (g-j) Immunohistochemical staining of mutant (g, i) and control (h, j) glands using an antibody to ERa (g, h) and BrdU (i, j). BrdU, 5-bromodeoxyuridine; ERa, estrogen and its receptor alpha.
ERa signaling in BRCA1-associated tumorigenesis W Li et al Next, we examined expression of ERa in mammary hyperplasias and tumors. We found that majority of cells in hyperplasia (95.871.94%, Figure 2a ), carcinoma in situ (94.771.93%, Figure 2b ), and small tumors (o0.5 cm in diameter) (82.473.39%, Figure 2c ) (n ¼ 27) expressed ERa. However, ERa expression gradually diminished along with tumor progression. Our data detected less than 1% cells remained ERa-positive in big tumors (B2 cm, Figure 2d ) (n ¼ 19), despite these tumors exhibited diverse histology. It was shown previously that estrogen/ERa signaling could trigger extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation (Migliaccio et al., 1996) . Our analysis revealed that expression pattern of ERK1/2 phosphorylation was similar to ERa, that is, it was present in hyperplasia and small tumors (Figure 2e-g) and extinguished in larger tumors ( Figure 2h ). These observations were confirmed by western blot analyses (Figure 2m and n). It is conceivable that the bigger tumors were able to grow, although they had lost ERa expression. Consistently, we found that all the tumors were highly positive for BrdU (Figure 2o ). ERa signaling in BRCA1-associated tumorigenesis W Li et al 1999). Therefore, it has been proposed that ERapositive cells work in a paracrine fashion by secreting growth factors that promote their ERa-negative neighbors to proliferate (Clarke et al., 1997; Russo et al., 1999) . To investigate this, we determined effects of increased ERa/ERK1/2 signaling on cell proliferation in vivo. Our colocalization study using antibodies to ERa and Ki67 indicated that only 0.7770.4% ERa-positive cells were Ki67-positive in control mammary glands (Figure 3a ). This observation is consistent with previous findings that ERa-expressing mammary epithelial cells do not proliferate. In contrast, many (28.973.8%) ERa-positive cells were also Ki67-positive in BRCA1-mutant mammary glands ( Figure 3b ) and in smaller tumors (data not shown). We next performed colocalization of ERK1/2 phosphorylation with BrdU and found that virtually all BrdU-positive cells colocalized with ERK1/2-pi in the early stage of tumorigenesis ( Figure 3c ). These observations indicate that the absence of BRCA1 reversed the paracrine growth mechanism and allowed BRCA1-mutant cells to proliferate in an autocrine or endocrine fashion. Next, we performed immunohistochemical staining with cyclin D1, which is known to promote cell progression into S phase. Our data indicated that these cells displayed markedly increased nuclear expression of cyclin D1 and that cyclin D1 also colocalized with ERa in the smaller tumors (Figure 3d ). This observation indicates that the absence of BRCA1 increases ERK1/2 phosphorylation and nuclear expression of cyclin D1, which may account for the autocrine/endocrine proliferation of BRCA1-mutant cells. Interestingly, cyclin þ /À mice. BrdU, 5-bromodeoxyuridine; ERa, estrogen and its receptor alpha; ERK1/2, extracellular signal-regulated kinase 1/2; MAPK, mitogen-activated protein kinase.
ERa signaling in BRCA1-associated tumorigenesis W Li et al D1 expression also diminished in the later stages of the tumorigenesis similar to ERa and ERK1/2-pi (Figure 2i-l) .
The absence of full-length BRCA1 sensitized cells to estrogen-induced ERK1/2 activation Next, we studied relationship between BRCA1 mutation and ERK1/2 activation. Our data indicated that a mammary epithelial cell line (C6) derived from a premalignant mammary gland of a Brca1
mouse was more sensitive than a control cell line (B10) derived from a Brca1
;p53 þ /À mouse to ERK1/2 phosphorylation induced by E2 (Figure 4a) . Similarly, mammary tumor cells (W780) derived from BRCA1-mutant mice were more sensitive to E2-induced ERK1/2 activation than mammary tumor cells (c-Neu) derived from an MMTV-c-neu transgenic mouse (Figure 4b) . Furthermore, mammary explants from Brca1
mice responded to E2 treatment by activating ERK1/2, while such activation was not observed in mammary explants of p53 þ /À control mice (Figure 4c ). To investigate whether living mice could respond to estrogen, we implanted estrogen beads into Brca1
D11/D11
;p53 þ /À and p53 þ /À mice and extracted proteins from the mammary gland of these mice 7 and 40 days later. Western blot analysis revealed that Brca1
;p53 þ /À mice showed higher levels of ERK1/2 phosphorylation than control mice at both time points (Figure 4d ).
Estrogen increased cyclin D1 expression and enhances cell proliferation Our data thus far revealed the following two interesting findings: (1) BRCA1 deficiency sensitizes cells to ERK1/ 2 phosphorylation induced by E2, and (2) BRCA1-mutant cells exhibit higher levels of ERK1/2 phosphorylation and increased BrdU labeling. These observations suggest that E2 may stimulate cell proliferation by inducing ERK1/2 phosphorylation. To confirm this, we studied whether E2 stimulates cell proliferation by inducing ERK1/2 phosphorylation. We found that estrogen-treated cells maintained high levels of ERK1/ 2-pi during the entire treatment period of 8 h (Figure 5a ). At the same time, cyclin D1 expression was upregulated 2 h after the treatment. Upregulation of cyclin D1 requires ERK1/2 activation since levels of cyclin D1 expression were markedly decreased by the treatment of PD98059 (a specific MEK (mitogenactivated protein kinase/extracellular signal-regulated kinase kinase) inhibitor), which inhibited both basal and E2-induced ERK1/2 phosphorylation (Figure 5a ). Estrogen treatment also resulted in faster proliferation of BRCA1-mutant cells than control cells (Figure 5b and c). We showed that the increased cell proliferation by E2 could also be inhibited by PD98059 (Figure 5d ), suggesting that both ERK1/2 activation and cyclin D1 expression are required for the cell proliferation.
BRCA1 inhibits ERK1/2 phosphorylation induced by estrogen
The observation that the absence of BRCA1 increased ERK1/2 phosphorylation by estrogen stimulation suggests that BRCA1 inhibits ERK1/2 phosphorylation induced by E2. To provide direct evidence for this, pCMS-EGFP and pCMS-EGFP-BRCA1 were transfected into W780 cells. We found that the expression of BRCA1, but not green fluorescent protein (GFP), inhibited ERK1/2 phosphorylation induced by E2 treatment (Figure 5e and f). We have also used immunofluorescent staining to determine the effect of BRCA1 expression on ERK1/2 phosphorylation. We found that 78% of GFP-transfected W780 cells were ERK1/2-pi-positive upon estrogen treatment, whereas only about 30% of the GFP-BRCA1-transfected cells were ERK1/2-pi-positive (Figure 5g and h ). These data indicated that BRCA1 indeed inhibited ERK1/2 phosphorylation induced by estrogen.
Estrogen promotes mammary tumor formation in the BRCA1-mutant mice To test if increased estrogen signaling could increase the frequency of mammary tumor formation, we next ectopically supplied estrogen by implanting estrogensoaked beads underneath the skin of mutant mice carrying a mammary-specific mutation of Brca1 (Brca1
;WAP-Cre) (Xu et al., 1999) . We found that 60% (9/15) of Brca1 co/D ;p53 þ /À ;WAP-Cre mice that received estrogen pellet developed mammary tumors within 1 year of age while no mammary tumors were detected in estrogen-treated p53 þ /À control mice (n ¼ 11). p53 þ /À mice that were treated with estrogen beads for 7 or 40 days. Fold of ERK-pi increase was measured from at least three independent samples and was indicated underneath each gel. ERa, estrogen and its receptor alpha; ERK1/2, extracellular signalregulated kinase 1/2; MAPK, mitogen-activated protein kinase. To investigate whether estrogen/ERa-mediated ERK1/2 activation is involved in the tumor formation, we studied the mammary glands of estrogen-or placebotreated mice. Our analysis indicated that estrogen treatment for 40 days increased mammary branching morphogenesis in both BRCA1-mutant and control mice, although a significantly increased alveolarization was only observed in BRCA1-mutant mice (Figure 6a-c) .
Both ERa (Figure 6d ) and ERK1/2-pi ( Figure 6e ) were expressed at much higher levels in treated mice than in untreated mice. These observations are consistent with our earlier findings that the absence of BRCA1 increases estrogen/ERa/ERK1/2-pi signaling, which contributes to mammary tumorigenesis in BRCA1 mutant mice.
Discussion
In this study, we have investigated the genetic interplay between BRCA1 and the estrogen/ERa signaling pathway during mammary tumorigenesis. We found that ERa and a number of its downstream genes were highly expressed in the premalignant mammary gland and early stages of tumorigenesis in BRCA1-mutant mice but that their expression was extinguished at later stages of tumor development. This finding provides a molecular basis for the involvement of estrogen signals in early stages of BRCA1-associated breast cancer formation. Furthermore, we demonstrated that estrogen treatment increased BRCA1-mutant cell proliferation in vitro and mammary tumor formation in vivo. These observations provide compelling genetic evidence that estrogen/ERa signaling plays an important role in BRCA1-associated tissue-specific tumor formation.
Clinical and epidemiological investigations indicate that estrogen plays a critical role in the development of breast cancer (Russo and Russo, 1998) . It was shown that targeted disruption of ERa impaired mammary gland development (Korach et al., 1996) , while removal of ovaries decreased mammary alveolarization and branching morphogenesis (Bachelier et al., 2005) . Consistent with higher levels of estrogen receptor and its downstream genes, the mammary gland of BRCA1-mutant mice displayed significantly more extensive branching and alveolarization, as well as increased BrdU incorporation. It has been shown that human BRCA1 mutation carriers tend to have higher density breast tissues, which could be a consequence of an increased estrogen/ERa signaling (Huo et al., 2002) .
A number of studies indicated that estrogen/ERa signaling promotes cell proliferation in a paracrine fashion, that is, ERa-expressing cells do not normally proliferate, but instead stimulate proliferation of their neighbors (Clarke et al., 1997; Russo et al., 1999) . Our data indicated that this is largely attributed to the presence of BRCA1 in these cells, as a significant fraction of ERa-positive cells can proliferate when their BRCA1 is deleted. Thus, the absence of BRCA1 turns cell proliferation from a paracrine to an autocrine or endocrine mechanism. It is known that MAP kinase and cyclin D1 play important roles in breast cancer formation (reviewed by Santen et al., 2002) . Our analysis revealed that the treatment of estrogen induces ERK1/2 phosphorylation and cyclin D1 expression in BRCA1-mutant cells but not in BRCA1 wild-type cells, nor in BRCA1-mutant cells that were transfected by a wtBRCA1. This finding indicates that the absence of BRCA1 sensitizes cells to estrogen/ERa-mediated ERa signaling in BRCA1-associated tumorigenesis W Li et al ERK1/2 phosphorylation and increased cyclin D1 expression, which provides a basis for the estrogeninduced cell proliferation.
Notably, all tumors developed in our BRCA1-mutant mice are ERa-positive at their early stages and gradually become ERa-negative at later stages of development. The reasons for this reduction are currently unclear. It is possible that ERa expression in the tumor initiation stages facilitates cell proliferation but at later stages it may restrict cell proliferation, as E2 could induce DNA damage that BRCA1-mutant cells cannot repair because of their deficiency in the multiple DNA damage repairing pathways (Deng and Wang, 2003; Zhang and Powell, 2005) . It is conceivable that these ERa-positive cells gradually lose their ERa expression due to epigenetic modifications, which allows them to proliferate leading to the formation of full-grown tumors. Nonetheless, the precise mechanism underlying the decreased expression of ERa during tumor progression is an interesting issue and deserves further investigations in the near future.
We are unable to determine the contribution of estrogen/ERa/ERK1/2 signaling in ovarian cancer formation in this study because the Brca1 D11/D11 p53 þ /À mice died within 1 year of age . However, recent studies revealed that BRCA1 inhibits estrogen biosynthesis through modulating aromatase expression in ovarian granulosa cells (Hu et al., 2005) , and conditional mutation of Brca1 in granulosa cells results in ovarian tumor formation (Chodankar et al., 2005) , suggesting that the breast and ovary may share a similar mechanism underlying BRCA1-associated tissue-specific tumorigenesis.
Materials and methods
Mice and treatment
;WAP-Cre mice were generated as described (Xu et al., 1999 þ /À mice that have been gone through two pregnancies to activate WAP-Cre. All the mice were about 4 months of age when E2 beads were implanted. Mice were killed at 7 or 40 days after E2 treatment, or kept for long-term tumorigenesis study. The mice are in a mix background of 129/Black Swiss/FVB. All experiments ;p53
) were established following an established procedure (Deng and Xu, 2004) . These cells were maintained in the Dulbecco's modified Eagle's medium (DMEM) with 5 mg/ml bovine insulin and 10 ng/ml mouse epidermal growth factor. BRCA1-mutant mammary tumor cell line, W780, BRCA1 wild-type mammary tumor cells, c-Neu (Brodie et al., 2001 ) and MCF7 cell were cultured in DMEM with 5-10% fetal bovine serum. For estrogen treatment, cells were plated in dishes at 50% confluence under normal conditions. The next day, cells were fed with DMEM medium without phenol red and fetal calf serum. After starving 2 days, cells were treated with estrogen (10 nM) (Sigma, St Louis, MO, USA) for 5 min for short-term effect on ERK1/2 phosphorylation, and for 30 min, 2, 4, 6 and 8 h for estrogen longterm effects. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was used for monitoring cell proliferation.
Mammary gland explants and treatment
The mammary glands from both Brca1
D11/D11
;p53 þ /À and Brca1 þ / þ ;p53 þ /À mice at about 2 months of age were removed, cut into small (1-3 mm) pieces and cultured in phenol red-free medium 199 (Invitrogen, Carlsbad, CA, USA) with 1% bovine serum albumin and 5 mg/ml insulin with or without 100 nM estrogen for 24 h.
Western blot analysis, immunohistochemical and immunofluorescent staining Western blot analysis was performed using the following antibodies: ERa (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), cyclin D1 (1:1000, Santa Cruz Biotechnology), ERK1/2-pi (1:1000, Cell Signaling Technology, Danvers, MA, USA), ERK1/2 (1:000, Cell Signaling Technology), BRCA1 (1:500; Turner et al., 2004) and b-actin (1:10 000, Sigma). Antibodies used for immunohistochemical or immunofluorescent staining were ERa (1:200, Santa Cruz Biotechnology), cyclin D1 (1:200, Pharmingen, Franklin Lakes, NJ, USA), ERK1/2-pi (1:200, Cell Signaling Technology), Ki67 (1:1000, Novocastra, Newcastle upon Tyne, UK) and BrdU (1:500, Zymed Laboratories Inc., South San Francisco, CA, USA).
Statistical analysis
Numbers of mammary branches and alveoli of BRCA1-mutant and control mice within arbitral areas of same size were counted under high power of microscope. Band intensity of western gel was measured by a GS-800 calibrated densitometer (Bio-Rad, Hercules, CA, USA). All the values, including the ones obtained in the MTT assay were analysed by Student's t-test (http://www.physics.csbsju.edu/stats/t-test. html). Pp0.05 was considered statistically significant.
